Evaluation of the Robustness Verification of Downstream Production Process for Inactivated SARS-CoV-2 Vaccine and Different Chromatography Medium Purification Effects
Background: Large-scale vaccine production requires downstream processing that focuses on robustness, efficiency, and cost-effectiveness. Methods: To assess the robustness of the current vaccine production process, three batches of COVID-19 Omicron BA.1 strain hydrolytic concentrated solutions were...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/12/1/56 |
| _version_ | 1827369303387668480 |
|---|---|
| author | Jia-Hui Pang Chang-Fu Guo Peng-Liang Hao Sheng-Li Meng Jing Guo Dou Zhang Ya-Qi Ji Ping-Gang Ming |
| author_facet | Jia-Hui Pang Chang-Fu Guo Peng-Liang Hao Sheng-Li Meng Jing Guo Dou Zhang Ya-Qi Ji Ping-Gang Ming |
| author_sort | Jia-Hui Pang |
| collection | DOAJ |
| description | Background: Large-scale vaccine production requires downstream processing that focuses on robustness, efficiency, and cost-effectiveness. Methods: To assess the robustness of the current vaccine production process, three batches of COVID-19 Omicron BA.1 strain hydrolytic concentrated solutions were selected. Four gel filtration chromatography media (Chromstar 6FF, Singarose FF, Bestarose 6B, and Focurose 6FF) and four ion exchange chromatography media (Maxtar Q, Q Singarose, Diamond Q, and Q Focurose) were used to evaluate their impact on vaccine purification. The quality of the vaccine was assessed by analyzing total protein content, antigen content, residual Vero cell DNA, residual Vero cell protein, and residual bovine serum albumin (BSA). Antigen recovery rate and specific activity were also calculated. Statistical analysis was conducted to evaluate process robustness and the purification effects of the chromatography media. Results: The statistical analysis revealed no significant differences in antigen recovery (<i>p</i> = 0.10), Vero HCP residue (<i>p</i> = 0.59), Vero DNA residue (<i>p</i> = 0.28), and BSA residue (<i>p</i> = 0.97) among the three batches of hydrolytic concentrated solutions processed according to the current method. However, a significant difference (<i>p</i> < 0.001) was observed in antigen content. Conclusions: The study demonstrated the remarkable robustness of the current downstream process for producing WIBP-CorV vaccines. This process can adapt to different batches of hydrolytic concentrated solutions and various chromatography media. The research is crucial for the production of inactivated SARS-CoV-2 vaccines and provides a potential template for purifying other viruses. |
| first_indexed | 2024-03-08T09:45:13Z |
| format | Article |
| id | doaj.art-fd2825ad1b864b3fa65bb759ca082805 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-08T09:45:13Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-fd2825ad1b864b3fa65bb759ca0828052024-01-29T14:25:38ZengMDPI AGVaccines2076-393X2024-01-011215610.3390/vaccines12010056Evaluation of the Robustness Verification of Downstream Production Process for Inactivated SARS-CoV-2 Vaccine and Different Chromatography Medium Purification EffectsJia-Hui Pang0Chang-Fu Guo1Peng-Liang Hao2Sheng-Li Meng3Jing Guo4Dou Zhang5Ya-Qi Ji6Ping-Gang Ming7National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, ChinaWuhan Institute of Biological Products Co., Ltd., Wuhan 430207, ChinaWuhan Institute of Biological Products Co., Ltd., Wuhan 430207, ChinaNational Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, ChinaNational Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, ChinaWuhan Institute of Biological Products Co., Ltd., Wuhan 430207, ChinaWuhan Institute of Biological Products Co., Ltd., Wuhan 430207, ChinaWuhan Institute of Biological Products Co., Ltd., Wuhan 430207, ChinaBackground: Large-scale vaccine production requires downstream processing that focuses on robustness, efficiency, and cost-effectiveness. Methods: To assess the robustness of the current vaccine production process, three batches of COVID-19 Omicron BA.1 strain hydrolytic concentrated solutions were selected. Four gel filtration chromatography media (Chromstar 6FF, Singarose FF, Bestarose 6B, and Focurose 6FF) and four ion exchange chromatography media (Maxtar Q, Q Singarose, Diamond Q, and Q Focurose) were used to evaluate their impact on vaccine purification. The quality of the vaccine was assessed by analyzing total protein content, antigen content, residual Vero cell DNA, residual Vero cell protein, and residual bovine serum albumin (BSA). Antigen recovery rate and specific activity were also calculated. Statistical analysis was conducted to evaluate process robustness and the purification effects of the chromatography media. Results: The statistical analysis revealed no significant differences in antigen recovery (<i>p</i> = 0.10), Vero HCP residue (<i>p</i> = 0.59), Vero DNA residue (<i>p</i> = 0.28), and BSA residue (<i>p</i> = 0.97) among the three batches of hydrolytic concentrated solutions processed according to the current method. However, a significant difference (<i>p</i> < 0.001) was observed in antigen content. Conclusions: The study demonstrated the remarkable robustness of the current downstream process for producing WIBP-CorV vaccines. This process can adapt to different batches of hydrolytic concentrated solutions and various chromatography media. The research is crucial for the production of inactivated SARS-CoV-2 vaccines and provides a potential template for purifying other viruses.https://www.mdpi.com/2076-393X/12/1/56SARS-CoV-2Vero cellsdownstream processpurificationvaccinessize-exclusion chromatography |
| spellingShingle | Jia-Hui Pang Chang-Fu Guo Peng-Liang Hao Sheng-Li Meng Jing Guo Dou Zhang Ya-Qi Ji Ping-Gang Ming Evaluation of the Robustness Verification of Downstream Production Process for Inactivated SARS-CoV-2 Vaccine and Different Chromatography Medium Purification Effects Vaccines SARS-CoV-2 Vero cells downstream process purification vaccines size-exclusion chromatography |
| title | Evaluation of the Robustness Verification of Downstream Production Process for Inactivated SARS-CoV-2 Vaccine and Different Chromatography Medium Purification Effects |
| title_full | Evaluation of the Robustness Verification of Downstream Production Process for Inactivated SARS-CoV-2 Vaccine and Different Chromatography Medium Purification Effects |
| title_fullStr | Evaluation of the Robustness Verification of Downstream Production Process for Inactivated SARS-CoV-2 Vaccine and Different Chromatography Medium Purification Effects |
| title_full_unstemmed | Evaluation of the Robustness Verification of Downstream Production Process for Inactivated SARS-CoV-2 Vaccine and Different Chromatography Medium Purification Effects |
| title_short | Evaluation of the Robustness Verification of Downstream Production Process for Inactivated SARS-CoV-2 Vaccine and Different Chromatography Medium Purification Effects |
| title_sort | evaluation of the robustness verification of downstream production process for inactivated sars cov 2 vaccine and different chromatography medium purification effects |
| topic | SARS-CoV-2 Vero cells downstream process purification vaccines size-exclusion chromatography |
| url | https://www.mdpi.com/2076-393X/12/1/56 |
| work_keys_str_mv | AT jiahuipang evaluationoftherobustnessverificationofdownstreamproductionprocessforinactivatedsarscov2vaccineanddifferentchromatographymediumpurificationeffects AT changfuguo evaluationoftherobustnessverificationofdownstreamproductionprocessforinactivatedsarscov2vaccineanddifferentchromatographymediumpurificationeffects AT penglianghao evaluationoftherobustnessverificationofdownstreamproductionprocessforinactivatedsarscov2vaccineanddifferentchromatographymediumpurificationeffects AT shenglimeng evaluationoftherobustnessverificationofdownstreamproductionprocessforinactivatedsarscov2vaccineanddifferentchromatographymediumpurificationeffects AT jingguo evaluationoftherobustnessverificationofdownstreamproductionprocessforinactivatedsarscov2vaccineanddifferentchromatographymediumpurificationeffects AT douzhang evaluationoftherobustnessverificationofdownstreamproductionprocessforinactivatedsarscov2vaccineanddifferentchromatographymediumpurificationeffects AT yaqiji evaluationoftherobustnessverificationofdownstreamproductionprocessforinactivatedsarscov2vaccineanddifferentchromatographymediumpurificationeffects AT pinggangming evaluationoftherobustnessverificationofdownstreamproductionprocessforinactivatedsarscov2vaccineanddifferentchromatographymediumpurificationeffects |